Matthew has extensive experience relating to the pharmaceutical industry having started his career in medicinal chemistry at GSK where he delivered small molecule development candidates for neurological indications, such as Alzheimer's Disease and neuropathic and inflammatory pain.
Matthew specializes in obtaining and defending rights relating to pharmaceutical subject matter including new chemical entities, crystal forms, synthetic processes, intermediates, formulations, combination products and medical uses. In addition to European patent drafting and prosecution, Matthew also manages the prosecution of patent portfolios worldwide, and also has experience of obtaining Supplementary Protection Certificates (SPCs) in many European countries.
He regularly provides advice to clients on EPO opposition and appeal strategy and has successfully defended and attacked patent rights covering various commercial products via the central opposition procedure at the EPO. Matthew also regularly assist his clients with due diligence activities associated with in-licencing, such as freedom-to-operate opinions.
Besides pharmaceuticals, Matthew has also helped his clients obtain and defend patent rights in relation to agrochemicals, catalysis, polymers and food science.
Chemistry and Pharmacology
Patent Attorney Litigator
Certificate in Intellectual Property Law
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.